Business Description
Silexion Therapeutics is an Israeli biotech company focused on fighting hard-to-treat cancers using a gene-silencing technology called RNAi. Its core innovation is the LODER platform, a miniature drug-delivery device designed to target tumors directly, with programs currently advancing against pancreatic cancer, prostate cancer, and an aggressive form of brain cancer. The company works alongside Evonik Corporation to refine its drug formulations and improve treatment outcomes. Founded in 2008 and based in Jerusalem, Silexion is working to turn a promising scientific approach into real therapies for patients with limited options.
